The drugmakers reported that their bapineuzumab compound failed to meet two primary endpoints and, consequently, they decided to discontinue additional Phase III research planned, although follow-up evaluations and final data analyses will be conducted ( back story).

FORBES: Lilly's Big Alzheimer's Bet: Will It Pay Off?